Aberdeen Group plc Increases Holdings in Tandem Diabetes Care, Inc. $TNDM

Aberdeen Group plc increased its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 67.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 598,096 shares of the medical device company’s stock after acquiring an additional 241,878 shares during the quarter. Aberdeen Group plc owned about 0.89% of Tandem Diabetes Care worth $7,261,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of TNDM. Royal Bank of Canada grew its position in Tandem Diabetes Care by 30.5% during the first quarter. Royal Bank of Canada now owns 211,666 shares of the medical device company’s stock valued at $4,054,000 after acquiring an additional 49,408 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Tandem Diabetes Care by 2.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,413 shares of the medical device company’s stock valued at $1,426,000 after purchasing an additional 2,096 shares during the period. Millennium Management LLC grew its position in shares of Tandem Diabetes Care by 41.1% in the 1st quarter. Millennium Management LLC now owns 227,585 shares of the medical device company’s stock worth $4,361,000 after buying an additional 66,245 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in shares of Tandem Diabetes Care during the first quarter valued at approximately $225,000. Finally, Goldman Sachs Group Inc. boosted its holdings in Tandem Diabetes Care by 5.0% in the first quarter. Goldman Sachs Group Inc. now owns 712,559 shares of the medical device company’s stock worth $13,653,000 after acquiring an additional 34,069 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Wells Fargo & Company boosted their target price on Tandem Diabetes Care from $13.00 to $14.00 and gave the stock an “equal weight” rating in a research report on Friday, November 7th. Bank of America upgraded shares of Tandem Diabetes Care from an “underperform” rating to a “neutral” rating and lifted their price objective for the company from $15.00 to $30.00 in a research report on Friday. Robert W. Baird set a $30.00 target price on Tandem Diabetes Care and gave the company an “outperform” rating in a research report on Tuesday, December 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Tandem Diabetes Care in a research report on Wednesday, January 21st. Finally, Mizuho set a $22.00 target price on shares of Tandem Diabetes Care and gave the company a “neutral” rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $25.50.

More Tandem Diabetes Care News

Here are the key news stories impacting Tandem Diabetes Care this week:

• Positive Sentiment: Q4 beat on top- and bottom-line metrics — revenue of $290.4M (vs. consensus ~$277M), EPS loss narrower than expected and record quarterly sales and pump shipments; management highlighted margin expansion. Tandem Diabetes Care Announces Fourth Quarter and Full Year 2025 Financial Results and 2026 Financial Guidance
• Positive Sentiment: Market reaction: shares surged intraday after the results and outlook, reflecting investor enthusiasm for the beat, margin momentum and sales growth. Tandem Diabetes Shares Rise 33% On Earnings Beat, Margin Expansion, Growth Outlook
• Positive Sentiment: Analyst upgrades/raise: BofA moved TNDM from Underperform to Neutral and raised its target to $30, and several analysts raised forecasts or price targets after the upbeat quarter. These upgrades support further upside momentum. B of A Securities upgrades Tandem Diabetes Care (TNDM)
• Neutral Sentiment: FY‑2026 revenue guidance (~$1.1B) was reiterated/issued and generally in line with consensus — provides visibility but isn’t a clear upside surprise. Tandem Diabetes Care Announces Fourth Quarter and Full Year 2025 Financial Results and 2026 Financial Guidance
• Neutral Sentiment: New pay-as-you-go (subscription) model announced — could expand long-term addressable market and recurring revenue but timing and transition impact are unclear. Tandem stock rises on Q4 beats, new pay-as-you-go model
• Negative Sentiment: Analyst caution: UBS and other analysts maintained Hold ratings, flagging pay‑go transition uncertainty and competitive headwinds that could limit near-term upside — supporting more conservative views. Tandem Diabetes Care: Solid Q4 Beat Offset by PayGo Transition Uncertainty and Competitive Headwinds Supporting Hold Rating
• Negative Sentiment: Mixed price-target moves: some firms raised targets but others (e.g., Stifel’s $22 target) still imply limited near-term upside versus the current price, underscoring divergent analyst views. Tandem Diabetes price target raised by Stifel

Tandem Diabetes Care Stock Up 32.7%

TNDM stock opened at $24.57 on Friday. The firm has a 50 day moving average of $20.91 and a 200 day moving average of $17.01. Tandem Diabetes Care, Inc. has a 52 week low of $9.98 and a 52 week high of $35.12. The company has a quick ratio of 1.90, a current ratio of 2.44 and a debt-to-equity ratio of 2.33. The stock has a market capitalization of $1.67 billion, a PE ratio of -8.00 and a beta of 1.68.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings data on Thursday, February 19th. The medical device company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.04. Tandem Diabetes Care had a negative return on equity of 70.01% and a negative net margin of 20.17%.The business had revenue of $290.38 million for the quarter, compared to analyst estimates of $277.14 million. During the same period in the prior year, the company earned $0.01 earnings per share. The company’s revenue was up 15.1% on a year-over-year basis. Sell-side analysts forecast that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current year.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.